Myriad Genetics' Sell Thesis Is 'Largely Played Out'
February 08, 2017 at 09:33 AM EST
Ladenburg Thalmann upgraded shares of Myriad Genetics, Inc. (NASDAQ: MYGN), premised on valuation, as it views that the sell thesis ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.